Caribou lays off 32% of staff, cuts lupus cell therapy program before first patient
Caribou Biosciences is paring down its pipeline and cutting about a third of its workforce as cell and gene therapy companies continue to struggle amid …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
